About CymaBay

Home /About / Management Team

Harold Van Wart, Ph.D. – President, Chief Executive Officer

Dr. Van Wart has served as our Chief Executive Officer and a member of the Board of Directors since January 2003, and President since April 2001. He served as Chief Operating Officer from December 2002 to January 2003 and Senior Vice President, Research and Development from October 2000 to December 2002. From 1999 to 2000, Dr. Van Wart was Vice President and Therapy Head for arthritis and fibrotic diseases at Roche Bioscience, a biopharmaceutical company. From 1992 to 1999, he was Vice President and Director of the institute of biochemistry and cell biology at Syntex Corporation, a biopharmaceutical company acquired by Roche Bioscience in 1994. From 1978 to 1992, Dr. Van Wart served on the faculty of Florida State University. He currently serves on the Emerging Companies and Health Section Governing Boards of the Biotechnology Industry Organization (BIO), as well as on its board of directors. He is also a Director of Conatus Pharmaceuticals, Inc. and is the Chairman of the California Life Sciences Association. Dr. Van Wart holds a Ph.D.

Sujal Shah – Chief Financial Officer

Mr. Shah joined CymaBay as Chief Financial Officer in December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer since June 2012. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking Group for Citigroup, where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah received a MBA from Carnegie Mellon University – Tepper School of Business in 2004 and a M.S. from Northwestern University in Biomedical Engineering in 1997.

Pol Boudes, M.D. – Chief Medical Officer

Dr. Boudes joined CymaBay in April 2014 as our Chief Medical Officer. Prior to joining CymaBay, Dr. Boudes was Chief Medical Officer at Amicus Therapeutics. From 2004 to 2009, Dr. Boudes was with Berlex Laboratories (which merged with Bayer HealthCare Pharmaceuticals in 2006) where he held the position of Vice President, Global Clinical Development, Women's Health Care US. From 1990 to 2004, he held positions of increasing responsibility with Wyeth-Ayerst Research both in Philadelphia, PA and in Europe, with Hoffmann-La Roche, and with Pasteur-Merieux Serums & Vaccines. Dr. Boudes received his M.D. from the University of Aix-Marseilles, France. He completed his internship and residency in Marseilles and in Paris, France and was an Assistant Professor of Medicine at the University of Paris. He is specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases.

Robert L. Martin, Ph.D. – Senior Vice President, Manufacturing and Nonclinical Development

Dr. Martin has been Senior Vice President, Manufacturing and Nonclinical Development since 2015. Previously, he served as our Vice President of Nonclinical Development and Project Management since 2008. Dr. Martin served as our Sr. Director of Preclinical Development and Project Management from 2006 to 2008 and our Director of Preclinical Development and Project Management from 2004 to 2006. From 1994 to 2004, Dr. Martin served in various positions of increasing responsibility with Roche Palo Alto, a division of F. Hoffman-La Roche Ltd. Dr. Martin obtained his Ph.D. in Biochemistry from the University of California, Davis.

Charles A. McWherter, Ph.D. – Senior Vice President and Chief Scientific Officer

Dr. McWherter has served as our Senior Vice President and Chief Scientific officer since 2013. Previously he served as our Senior Vice President, Research and Preclinical Development since July 2007. From 2003 to 2007, he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc. From 2001 to 2003, Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a subsidiary of Pharmacia acquired by Pfizer Inc. in 2003. Dr. McWherter obtained his Ph.D. from Cornell University.

Patrick J. O’Mara – Senior Vice President, Business Development

Mr. O’Mara joined CymaBay in 1991 and has served CymaBay in a variety of operational and business development positions. He has been Senior Vice President of Business Development since January 2017. Previously he served as our Vice President of Business Development since August 2006. Prior to joining CymaBay, Mr. O’Mara held positions on increasing responsibility at Thymax Corporation and Thomas Research Corp. Mr. O’Mara received a B.A. in Biochemistry from the University of California, Berkeley.

Kirk Rosemark – Vice President, Regulatory Affairs and Quality Assurance

Mr. Rosemark joined CymaBay as Vice President Regulatory Affairs and Quality Assurance in April 2015. Prior to joining he held the position of Vice President Regulatory Affairs and Quality Assurance at Exelixis, Inc. from 2003 to 2014, and served in the same capacity at NeoPharm Inc. Mr. Rosemark held various positions of increasing responsibility within the Regulatory Affairs and Quality Assurance functions at Solvay Pharmaceuticals, Inc., Ciba Vision and Bausch & Lomb Pharmaceuticals, Inc. Mr. Rosemark obtained a B.S. in Chemistry from Cleveland State University.